Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling

被引:183
作者
Hoefnagel, JJ
Dijkman, R
Basso, K
Jansen, PM
Hallermann, C
Willemze, R
Tensen, CP
Vermeer, MH
机构
[1] Leiden Univ, Med Ctr, Dept Dermatol, NL-2300 RC Leiden, Netherlands
[2] Leiden Univ, Med Ctr, Dept Pathol, NL-2300 RC Leiden, Netherlands
[3] Columbia Univ, Inst Canc Genet, New York, NY USA
[4] Univ Hosp Gottingen, Dept Dermatol, Gottingen, Germany
关键词
D O I
10.1182/blood-2004-04-1594
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the European Organization for Research and Treatment of Cancer (EORTC) classification 2 types of primary cutaneous large B-cell lymphoma (PCLBCL) are distinguished: primary cutaneous follicle center cell lymphomas (PCFCCL) and PCLBCL of the leg (PCLBCL-leg). Distinction between both groups is considered important because of differences in prognosis (5-year survival > 95% and 52%, respectively) and the first choice of treatment (radiotherapy or systemic chemotherapy, respectively), but is not generally accepted. To establish a molecular basis for this subdivision in the EORTC classification, we investigated the gene expression profiles of 21 PCLBCLs by oligonucleotide microarray analysis. Hierarchical clustering based on a B-cell signature (7450 genes) classified PCLBCL into 2 distinct subgroups consisting of, respectively, 8 PCFCCLs and 13 PCLBCLs-leg. PCLBCLs-leg showed increased expression of genes associated with cell proliferation; the proto-oncogenes Pim-1, Pim-2, and c-Myc; and the transcription factors Mum1/IRF4 and Oct-2. In the group of PCFCCL high expression of SPINK2 was observed. Further analysis suggested that PCFCCLs and PCLBCLs-leg have expression profiles similar to that of germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphoma, respectively. The results of this study suggest that different pathogenetic mechanisms are involved in the development of PCFCCLs and PCLBCLs-leg and provide molecular support for the subdivision used in the EORTC classification.
引用
收藏
页码:3671 / 3678
页数:8
相关论文
共 51 条
[1]   Molecular and clinical features of non-Burkitt's, diffuse large-cell lymphoma of B-cell type associated with the c-MYC/immunoglobulin heavy-chain fusion gene [J].
Akasaka, T ;
Akasaka, H ;
Ueda, C ;
Yonetani, N ;
Maesako, Y ;
Shimizu, A ;
Yamabe, H ;
Fukuhara, S ;
Uchiyama, T ;
Ohno, H .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (03) :510-518
[2]   Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].
Alizadeh, AA ;
Eisen, MB ;
Davis, RE ;
Ma, C ;
Lossos, IS ;
Rosenwald, A ;
Boldrick, JG ;
Sabet, H ;
Tran, T ;
Yu, X ;
Powell, JI ;
Yang, LM ;
Marti, GE ;
Moore, T ;
Hudson, J ;
Lu, LS ;
Lewis, DB ;
Tibshirani, R ;
Sherlock, G ;
Chan, WC ;
Greiner, TC ;
Weisenburger, DD ;
Armitage, JO ;
Warnke, R ;
Levy, R ;
Wilson, W ;
Grever, MR ;
Byrd, JC ;
Botstein, D ;
Brown, PO ;
Staudt, LM .
NATURE, 2000, 403 (6769) :503-511
[3]   Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc [J].
Allen, JD ;
Verhoeven, E ;
Domen, J ;
vanderValk, M ;
Berns, A .
ONCOGENE, 1997, 15 (10) :1133-1141
[4]   RETICULOHISTIOCYTOMA OF THE DORSUM [J].
BERTI, E ;
ALESSI, E ;
CAPUTO, R ;
GIANOTTI, R ;
DELIA, D ;
VEZZONI, P .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1988, 19 (02) :259-272
[5]   Posttranslational modification of Bcl-2 facilitates its proteasome-dependent degradation: Molecular characterization of the involved signaling pathway [J].
Breitschopf, K ;
Haendeler, J ;
Malchow, P ;
Zeiher, AM ;
Dimmeler, S .
MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (05) :1886-1896
[6]   VERY HIGH-FREQUENCY OF LYMPHOMA INDUCTION BY A CHEMICAL CARCINOGEN IN PIM-1 TRANSGENIC MICE [J].
BREUER, M ;
SLEBOS, R ;
VERBEEK, S ;
VANLOHUIZEN, M ;
WIENTJENS, E ;
BERNS, A .
NATURE, 1989, 340 (6228) :61-63
[7]   Rapamycin increases the cellular concentration of the BCL-2 protein and exerts an anti-apoptotic effect [J].
Calastretti, A ;
Rancati, F ;
Ceriani, MC ;
Asnaghi, L ;
Canti, G ;
Nicolin, A .
EUROPEAN JOURNAL OF CANCER, 2001, 37 (16) :2121-2128
[8]  
Cerroni L, 2000, BLOOD, V95, P3922
[9]   Expression of MUM1/ARF4 correlates with clinical outcome in patients with B-cell chronic lymphocytic leukemia [J].
Chang, CC ;
Lorek, J ;
Sabath, DE ;
Li, Y ;
Chitambar, CR ;
Logan, B ;
Kampalath, B ;
Cleveland, RP .
BLOOD, 2002, 100 (13) :4671-4675
[10]   Analysis of microarray data using Z score transformation [J].
Cheadle, C ;
Vawter, MP ;
Freed, WJ ;
Becker, KG .
JOURNAL OF MOLECULAR DIAGNOSTICS, 2003, 5 (02) :73-81